Allogene Therapeutics Inc.
ALLO | NASDAQ
$1.71
+$0.02 (+1.18%)
Sep 22, 2026, 12:47 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | 22K | 95K | 156K | 114.09M | n/a |
Cost of Revenue | 12.36M | n/a | n/a | 14.3M | n/a | 11.54M |
Gross Profit | -12.36M | 22K | 95K | -14.14M | 114.09M | -11.54M |
Operating Income | -206.93M | -273.2M | -327.74M | -335.54M | -180.19M | -258.24M |
Interest Income | 19.29M | 20.15M | 18.31M | 4.57M | 1.71M | 9.16M |
Pretax Income | -190.89M | -257.15M | -327.27M | -340.41M | -182.05M | -250.22M |
Net Income | -190.89M | -257.59M | -327.27M | -340.41M | -182.05M | -250.22M |
Selling & General & Admin | 56.78M | 65.21M | 71.67M | 79.31M | 74.11M | 65.26M |
Research & Development | 150.15M | 192.3M | 242.91M | 256.39M | 220.18M | 192.99M |
Other Expenses | -12.36M | 15.72M | 13.25M | -14.3M | n/a | -11.54M |
Operating Expenses | 194.57M | 273.22M | 327.83M | 321.4M | 294.28M | 246.7M |
Interest Expense | 1.08M | 181K | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 206.93M | 273.22M | 327.83M | 335.69M | 294.28M | 258.24M |
Income Tax Expense | n/a | 443K | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 220.62M | 194.81M | 156.93M | 143.15M | 135.82M | 120.37M |
Shares Outstanding (Diluted) | 220.62M | 194.81M | 156.93M | 143.15M | 135.82M | 120.37M |
EPS (Basic) | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 | -2.08 |
EPS (Diluted) | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 | -2.08 |
EBITDA | -177.45M | -243.33M | -313.07M | -326.12M | -171.6M | -238.68M |
EBIT | -189.81M | -256.97M | -327.27M | -340.41M | -182.05M | -250.22M |
Depreciation & Amortization | 12.36M | 13.64M | 14.2M | 14.3M | 10.45M | 11.54M |
Add to Watchlist
Select watchlists to add or remove ALLO